The Two-Drug Combo That Just Rewrote the Playbook for Breast Cancer's Worst Villain

Why This Combo Makes Biological Sense

To understand why pairing these two drugs works, you need to know what each one does.

Keytruda is a checkpoint inhibitor. Your immune system has built-in brakes that prevent it from attacking your own cells. Cancer hijacks those brakes to hide. Keytruda releases the brakes, letting immune cells recognize and attack tumors. It's been a blockbuster across dozens of cancer types, but in TNBC it needed a partner to really shine.

Trodelvy is an antibody-drug conjugate (ADC), which is basically a guided missile. It's an antibody that locks onto a protein on the surface of cancer cells, then delivers a potent chemotherapy payload directly inside. Less collateral damage to healthy tissue; more firepower where it counts.

Put them together and you get a one-two punch: Trodelvy weakens the tumor directly while Keytruda rallies the immune system to finish the job. The combination replaces traditional chemo in the regimen, which matters because standard chemotherapy tends to be blunt and exhausting for patients.

The Fine Print on Who Qualifies

Not every TNBC patient is eligible. The approval is limited to adults with unresectable locally advanced or metastatic disease (meaning the cancer can't be surgically removed or has spread) whose tumors score CPS ≥10 on a PD-L1 test. CPS, or Combined Positive Score, measures how much of a particular protein is present in the tumor environment.

About 38% of metastatic TNBC patients are PD-L1 positive at that threshold. Since TNBC itself is already a minority subtype of breast cancer, the eligible population is relatively focused. But "focused" in oncology still means thousands of patients per year who now have a better option than what existed before.

What Wall Street Thinks (and What It's Worried About)

Analysts are calling this a clear positive for Gilead's oncology franchise. Trodelvy generated roughly $1.013 billion in sales in 2025, driven primarily by breast cancer. A first-line approval should expand that pie, since earlier-line treatments generally reach more patients and are used for longer.

The market's enthusiasm comes with caveats, though. Gilead and Merck recently discontinued a Phase 3 trial testing this same combo in non-small cell lung cancer after an independent monitoring committee concluded a clear survival benefit was unlikely. That killed the dream of a broader Trodelvy-Keytruda franchise across multiple tumor types. The breast cancer win is real, but the lung cancer miss limits the combination's long-term ceiling.

For Merck, the approval barely registers as a stand-alone catalyst. The company's bigger headache is Keytruda's looming patent cliff around 2028, and whether its pipeline can plug the gap before biosimilars arrive. The TNBC label expansion is helpful, not heroic.

On Gilead's side, most analysts rate the stock a Buy or higher. Some bullish models project Gilead hitting about $38.1 billion in revenue by 2029, with Trodelvy and the HIV drug lenacapavir doing the heavy lifting. The TNBC approval supports those projections more than it dramatically raises them; analysts were already pricing in some success here.

The Competitive Battlefield Ahead

Trodelvy isn't the only ADC trying to conquer breast cancer. Enhertu (trastuzumab deruxtecan), from Daiichi Sankyo and AstraZeneca, dominates in HER2-positive and HER2-low disease. Datopotamab deruxtecan (Dato-DXd) is another emerging rival that could pressure Trodelvy's expansion plans.

The real commercial question is whether the Trodelvy-Keytruda combo can establish itself quickly enough in clinical practice to become the default choice before competitors crowd the field. First-mover advantage matters in oncology; once doctors get comfortable with a regimen and see it working in their patients, switching costs (both logistical and psychological) are real.

The Bigger Picture

Five years ago, a first-line TNBC patient had chemo and not much else. Two years ago, Keytruda plus chemo became the standard for PD-L1-positive patients. Now, an ADC-immunotherapy combination has leapfrogged that standard with better efficacy data.

The trajectory is clear: oncology is moving away from blunt-force chemotherapy and toward smarter, more targeted combinations. For patients with one of breast cancer's most feared subtypes, this approval represents a genuinely better option, not just another incremental tweak.

The survival data still needs time to mature. But for a cancer that has historically offered patients very little good news, 11.2 months of progression-free survival is a number worth celebrating.